Cargando…

Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a cystic lung disease of women resulting from mutations in tuberous sclerosis complex (TSC) genes that suppress the mammalian target of rapamycin complex 1 (mTORC1) pathway. mTORC1 activation enhances a plethora of anabolic cellular functions, mainly via the activat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evans, Jilly F., McCormack, Francis X., Sonenberg, Nahum, Krymskaya, Vera P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Mini-Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523142/ https://www.ncbi.nlm.nih.gov/pubmed/37758276 http://dx.doi.org/10.1183/16000617.0100-2023

Ejemplares similares

CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis
por: Evans, Jilly Frances, et al.
Publicado: (2021)

The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
por: Courtwright, Andrew M., et al.
Publicado: (2017)

Translational control and autism-like behaviors
por: Gkogkas, Christos G., et al.
Publicado: (2013)

Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor
por: Evans, Jilly F., et al.
Publicado: (2019)

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
por: Alain, Tommy, et al.
Publicado: (2012)

The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis
por: Gao, Nannan, et al.
Publicado: (2018)

The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
por: Platé, Manuela, et al.
Publicado: (2020)

Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells
por: Himes, Blanca E., et al.
Publicado: (2018)

Wild Type Mesenchymal Cells Contribute to the Lung Pathology of Lymphangioleiomyomatosis
por: Clements, Debbie, et al.
Publicado: (2015)

Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer
por: El-Chemaly, Souheil, et al.
Publicado: (2014)

mTOR signalling pathway - A root cause for idiopathic autism?
por: Ganesan, Harsha, et al.
Publicado: (2019)

The Translational Regulation in mTOR Pathway
por: Yang, Miaomiao, et al.
Publicado: (2022)

Role of mTOR Complex 1 Signaling Pathway in the Pathogenesis of Diabetes Complications; A Mini Review
por: Yarahmadi, Amir, et al.
Publicado: (2021)

mTOR signaling: implications for cancer and anticancer therapy
por: Petroulakis, E, et al.
Publicado: (2006)

mTOR signaling in VIP neurons regulates circadian clock synchrony and olfaction
por: Liu, Dong, et al.
Publicado: (2018)

Lost in translation? – Caveat to the application of the voter model in ecology and evolutionary biology
por: Oborny, Beáta
Publicado: (2023)

mTOR kinase is needed for the development and stabilization of dendritic arbors in newly born olfactory bulb neurons
por: Skalecka, Agnieszka, et al.
Publicado: (2016)

Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
por: Tan, Aaron C.
Publicado: (2020)

Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy
por: Wang, Ziwen, et al.
Publicado: (2014)

THU551 Glycoprotein-NMB (GPNMB) Is A Potential Lymphangioleiomyomatosis (LAM) Therapeutic Target And Biomarker
por: Gibbons, Erin, et al.
Publicado: (2023)

Syndecan-2: Old Player in a New Field
por: Obraztsova, Kseniya, et al.
Publicado: (2019)

mTOR Signaling, Translational Control, and the Circadian Clock
por: Cao, Ruifeng
Publicado: (2018)

FUS contributes to mTOR-dependent inhibition of translation
por: Sévigny, Myriam, et al.
Publicado: (2021)

The Roles of Post-Translational Modifications on mTOR Signaling
por: Yin, Shasha, et al.
Publicado: (2021)

Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis
por: Hirose, Masaki, et al.
Publicado: (2019)

Sorafenib inhibits invasion of multicellular organoids that mimic Lymphangioleiomyomatosis nodules
por: Koc-Gunel, Sinem, et al.
Publicado: (2023)

The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis
por: Miller, Suzanne, et al.
Publicado: (2018)

mTOR and MAPK: from localized translation control to epilepsy
por: Pernice, Helena F., et al.
Publicado: (2016)

Neuronal mTOR Outposts: Implications for Translation, Signaling, and Plasticity
por: Altas, Bekir, et al.
Publicado: (2022)

Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy——AKT/m-TOR Pathway and Resistance to Cancer Therapy
por: SPIRINA, Liudmila V, et al.
Publicado: (2018)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Translation of Human β-Actin mRNA is Regulated by mTOR Pathway
por: Eliseeva, Irina, et al.
Publicado: (2019)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Translational Regulation of GPx-1 and GPx-4 by the mTOR Pathway
por: Reinke, Emily N., et al.
Publicado: (2014)

Assessment of mTOR-Dependent Translational Regulation of Interferon Stimulated Genes
por: Livingstone, Mark, et al.
Publicado: (2015)

mTOR-sensitive translation: Cleared fog reveals more trees
por: Masvidal, Laia, et al.
Publicado: (2017)

The Importance of mTOR Trafficking for Human Skeletal Muscle Translational Control
por: Hodson, Nathan, et al.
Publicado: (2019)

Host Translation at the Nexus of Infection and Immunity
por: Mohr, Ian, et al.
Publicado: (2012)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_oet1339lbpnl2th9eku4sbr4uf